SCHEMBL7528396

SCHEMBL7528396

N#Cc1ccccc1N1CCCCCC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.62
HRH3 Q9Y5N1 1/20 0.54
ALDH1A1 P00352 4/20 0.54
MAPT P10636 2/20 0.54
POLB P06746 1/20 0.54
KEAP1 Q14145 1/20 0.53
KDM4E B2RXH2 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MAPK1 P28482 1/20 0.52
GAA P10253 1/20 0.48
HTT P42858 1/20 0.47
LMNA P02545 1/20 0.47
MMP1 P03956 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
GRM5 P41594 1/20 0.47
ROCK2 O75116 1/20 0.46
ROCK1 Q13464 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31388194 1.00 AR (0.62) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL7524105 1.00 AR (0.62) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL1660394 1.00 AR (0.62) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL829177 0.98 AR (0.65) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL30406641 0.94 AR (0.59) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL3088832 0.89 DRD4 (0.54) ARALDH1A1MAPTKDM4EGAA
SCHEMBL1871089 0.86 ALDH1A1 (0.67) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL573134 0.86 ALDH1A1 (0.67) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL1878340 0.84 ALDH1A1 (0.69) ARHRH3ALDH1A1MAPTPOLB
SCHEMBL20142712 0.83 ALDH1A1 (0.50) ARHRH3ALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives OSI PHARMACEUTICALS, INC. 2002-12-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193389-A1 Method of inhibiting neoplastic cells with imidazoquinazoline derivatives MKI67, HRAS, VHL AR 3316/4885HRH3 1964/4885ALDH1A1 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.